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Some stem cell lines may contain an endogenous virus or can be contaminated with exogenous viruses (even of animal origin) and may secrete
viral particles or express viral antigens on their surface. Moreover, certain biotechnological products (e.g. bovine fetal serum, murine feeder cells)
may contain prion particles. Viral and prion contamination of cell cultures and ‘‘feeder’’ cells, which is a common risk in all biotechnological
products derived from the cell lines, is the most challenging and potentially serious outcome to address, due to the difficulty involved in virus and
prion detection and the potential to cause serious disease in recipients of these cell products.
Stem cell banks should introduce adequate quality assurance programs like the microbiological control program and can provide researchers
with valuable support in the standardization and safety of procedures and protocols used for the viral and prion testing and in validation programs
to assure the quality and safety of the cells.
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The new treatments of cell therapy based on the transplant of
cells of human origin still have problems, such as the difficulties
of culture and differentiation of the cells, the possibility of
chromosomal alterations and potential for tumorigenicity. Of
particular importance is the possibility of transmission of
infectious diseases to the recipients of these cell products.
Any microbial contamination of the donor’s biological products
or introduced during manufacturing process can potentially
present a serious hazard to recipients even if it is not an overt
pathogen. The most common potential forms of contamination
(e.g. bacteria (include mycoplasma), yeast, fungi) can be readily
assessed on a routine basis (European Pharmacopeia, 2004a,
2004b; Cobo et al., 2005). However, viral contamination of cell
cultures and feeder cells, which is a common risk in all
biotechnological products derived from the cell lines, is the
most challenging and potentially serious outcome to address,
due to the difficulty involved in virus detection and the potential
to cause serious disease in recipients of these cell products
(Cobo et al., 2005).0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.11.026
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for these applications, it is necessary to regulate the procure-
ment, processing, testing, preservation, storage and distribution
of all cells that will apply in the human body (Directive 2004/
23/CE). Stem cell banks must assure the quality and safety of
these cells, and these aims are particularly important in the
avoidance of transmissible diseases like viral and prion
infections that are difficult to diagnose. These establishments
should introduce adequate quality assurance programs like the
microbiological control program. In this respect, accredited
stem cell banks can provide researchers with valuable support
in the standardization and safety of procedures and protocols
used for viral and prion testing and in validation programs to
assure the quality and safety of the cells.
This review will discuss the methodology that should be used
in the stem cell banks in order to assure the quality of cell and
biotechnological products and avoid the transmission of infec-
tions, in particular those that involve virus and prion particles.
Viral and prion contamination sources of stem cell lines
Some lines or cell cultures may contain an endogenous virus
or can be contaminated with exogenous viruses, and may
secrete viral particles or express viral antigens on their surface.006) 1 – 10
www.e
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serum) may contain prionic particles. The primary sources of
potential viral and prionic contamination come from infected
animal tissue used to prepare biological reagents and media,
biological products from donors (e.g. bone marrow, preem-
bryos) and contamination during laboratory manipulation. In
addition, infected laboratory workers may cause contamination
of stem cell lines during culture manipulation.
Contamination by virus in ‘‘feeder’’ cells of animal origin
The requirement for ‘‘feeder’’ cells of animal origin (e.g.
murine cells) to maintain undifferentiated growth in human
Embryonic Stem Cells (hESCs) cultures provides intimate
contact between the potential therapeutic cells and the feeder
cells which are an ideal setting to transmit infectious micro-
organisms or bioactive molecules in the final therapeutic
product. There is evidence that certain mouse viruses, like
Hantaan virus, lymphocytic choriomeningitis virus (LCMV)
and reovirus-3 have all been detected in mouse colonies (Kraft
and Meyer, 1990) and these viruses have notably caused serious
infection, and even fatalities in laboratory workers (Lloyd and
Jones, 1986; Mahy et al., 1991) and may also be transmitted in
cell lines and reagents (Nicklas et al., 1993). Furthermore, in the
guidelines released by the European Medicines Evaluation
Agency (EMEA, 1997), there is evidence that other mouse
viruses like Hantaan virus, reovirus-3, Sendai virus, lactic
dehydrogenase virus and LCMVare capable of infecting humans
or primates. Finally, an additional group of murine viruses like
ectromelia virus, Minute virus of mice, mouse adenovirus,
mouse cytomegalovirus, mouse rotavirus, pneumonia virus of
mice, Toolan virus and Kilham rat virus, while not known to
cause human disease, are capable of replying in vitro in cells of
human or primate origin (EMEA, 1997).
Contamination by virus in ‘‘feeder’’ cells of human origin
In the event of using feeder cells of human origin (Draper et
al., 2004; Genbacev et al., 2005), there are numerous viruses
and other infectious agents that are susceptible to being
transmitted to the recipient because all human cells have the
potential to transmit infectious diseases. The screening should
apply to testing for human feeder cells for clinical use, the same
as the present regulations that require the screening of cell and
tissue products from donors for a spectrum of viruses which
cause serious human infectious diseases (UK MSBT, 2000;
AATB, 2002). Virological screening should firstly be carried
out for HIV-1/2, hepatitis B and hepatitis C; moreover, recently,
the products for transfusion containing cellular material have
been tested for the cell associated organisms such as hCMV
and HTLV-I/II (Consensus Document, 1999), although tests for
hepatitis A and hepatitis E should also be recommended in
such products. Other potentially viral agents that could be
contaminants of cells from healthy individuals include human
herpesviruses (HHV-6, HHV-7, HHV-8, Epstein–Barr virus,
herpes simplex virus), parvovirus B19, TTV virus and human
polyomaviruses (JC and BK virus), and these viruses remainlatent and detectable in humans from early childhood. The risk
of transmission of these microorganisms is considered ex-
tremely low, so tests for them are not currently required for
transplantation. However, the oncogenic risk of viral contam-
ination must also be considered because some of these agents
have been involved in human cancers (Takeuchi et al., 1996;
Garbuglia et al., 2003).
Some microbial agents have marked variation in their
geographical distribution, producing infectious epidemics in
different areas like the lymphocytic choriomeningitis virus in
USA (WNV Update, 2004) and the very recent outbreak of
severe acute respiratory syndrome (SARS) virus in humans in
South East Asia. Furthermore, two new retroviruses (HTLV-3
and HTLV-4) have been recently identified among African
bush-meat hunters (Wolfe et al., 2005) and recent cases of
transplant transmitted disease due to rabies virus in USA and
Germany (Srinivasan et al., 2005) have been reported, which
clearly shows the potential emergence of new serious patho-
gens or the re-emergence of known pathogens. Obviously, any
new entity that arises should be considered as a contamination
risk factor, and specific tests may be required, and these may be
developed for surveillance initiatives, as in the case of SARS,
for which detection methods are being developed for the
causative coronavirus agent (Juang et al., 2004).
Cell culture contamination by prions
The use of bovine fetal serum in stem cell cultures requires
an urgent need for a risk assessment for Transmissible
Spongiform Encephalopathies (TSEs) by means of a sensitive
and specific test in all products derived from ruminants (U.S.
Food and Drugs Administration, 1999; Directive 2004/C 24/
03). Cell cultures represent a good medium to promote and to
allow a persistent replication of PrPSc and to maintain the
infectivity, even for heterologous cell culture models (Solassol
et al., 2003). Human beings can be exposed to secondary
infections of TSE using medical procedures or by administer-
ing biological products derived from humans including blood
(Llewelyn et al., 2004; Peden et al., 2004). Thus, preventive
measures should be taken into account with respect to blood
products, cell or tissue grafts in order to avoid prion
transmission in the recipients.
Methods for viruses diagnosis from cell cultures
In vitro assay for viral detection: viral culture
Viruses are obligate intracellular parasites that require living
cells in order to replicate; since viruses require cellular
machinery for replication, living systems must be used. The
viral culture is an amplification method that increases the
amount of the pathogen, facilitating detection and character-
ization. This method is unique among detection methods in that
it provides an isolate of viable virus that can be further
characterized and stored for future studies. Another important
feature is that culture methods allow the detection of many
different viruses, including some not suspected at the time the
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be discovered.
A cell lysate or other specimens (e.g. biological products,
specimens from donors) should be introduced into the cell
culture capable of detecting wide ranges of viruses. The
instructions for obtaining and transporting such specimens
have been previously reported (Storch, 2001). Usually, a
minimum of three cell lines that include a human diploid cell
line (MRC-5), a monkey kidney cell line (Vero) and a cell type
of the same species and tissue type used for production (Schiff,
2005) is recommended. Additional cells may be required
depending on the cell source, passage history and raw materials
used. After inoculation, cultures are incubated at 35 to 37 -C
for either 14 or 28 days and inspected periodically (e.g. daily)
and observed for the cytopathic effect of several viruses,
including the recently reported method of analysis of HIV virus
cytopathicity by using Hi-CD4 Jurkat T cells cultures (Speirs et
al., 2005). In certain circumstances, the observation period can
be greater than 28 days for the identification of many viruses
(e.g. human cytomegalovirus).
Virus detection by testing the inoculated cell culture for
hemadsorption and/or hemagglutination (Ayala et al., 2004)
should be necessary for viruses with only minimal visible
cytopathic effect.
However, viral culture also has significant disadvantages as
a diagnostic method, including the need for specialized
facilities and expertise, expense and relatively prolonged time
to detection.
In vivo assay for viruses detection
The European Medicines Evaluation Agency (EMEA,
1997) and the U.S. Food and Drugs Administration (U.S.
Food and Drugs Administration, 1998) recommend the use of
studies in animals as a screening method for a wide range of
viruses. These studies consist of inoculation in mice, pigs and
embryonated chicken eggs of the cell lysate or biological
products that can cause clinical changes in animals.
Species-specific viruses that are potentially present in rodent
cells or stem cells with murine feeders are tested by the
antibody production test like the mouse, hamster and rat test
[MAP (16 murine viruses), HAP (5 viruses) and RAP (9
viruses)]. These tests are carried out by inoculating into virus-
free animals and then after a specific time, examining the serum
antibody levels.
However, these tests can take a number of weeks, and
therefore, can prove difficult to implement in the scheduling for
release testing of time critical products.
Electron microscopy
Viral infections can occasionally be diagnosed using
electron microscopy for the direct visualization of viral
particles in specimens. With the introduction of negative
staining in the late 1950s (Brenner and Horne, 1959) and the
wider availability of electron microscopes, electron microscopy
became essential in characterizing many new isolates detectedin cell cultures and clinical samples (Plummer et al., 1985; Biel
and Gelderblom, 1999). Pattern recognition (e.g. information
of size, particle morphology) leads to rapid identification of
infectious agents. The ‘‘open procedure’’ of electron micro-
scopic testing allows an unbiased, rapid detection of viruses
and other agents if sufficiently high particle concentrations
exist. Due to this capability, electron microscopic testing must
be a frontline method applied to cell cultures of cultivable
agents. A specimen can be ready for examination and an
experienced virologist or technologist can identify, by electron
microscopy, a viral pathogen morphologically within a few
minutes of arrival in the electron microscopy laboratory.
Other advantages of electron microscopy include the lack of
requirement for viral viability, the fact that many different
kinds of viral particles can potentially be seen, and allow the
differential diagnosis of many agents contained in the
specimen. Disadvantages include the cost and complexity of
maintaining an electron microscope (although this fact can be
corrected by working with other institutions with centralized
services), the need for a skilled operator and relative lack of
sensitivity related to the fact that a relatively high concentration
of viral particles (105 to 106 per milliliter) is required for
visualization (Miller, 1995). With respect to these questions,
there is a paper in which these relevant points are discussed
(Biel and Madeley, 2001).
There are two types of electron microscopy methods: direct
or immunoelectron microscopy. With direct methods, negative
staining is normally used which requires little special equip-
ment, in contrast to thin sectioning techniques. The specimens
may be used directly or the virus particles may be concentrated
before negative staining. Several methods are available for
concentration, including differential centrifugation, ammonium
persulfate precipitation and the agar diffusion method. Immu-
noelectron microscopy is a means of increasing the sensitivity
and specificity of electron microscopy and is particularly useful
if the number of virus particles present is small.
Details for efficient sample collection, preparation and
particle enrichment have been published previously (Gelder-
blom and Hazelton, 2000; Hazelton and Gelderblom, 2003).
Detection of viral antigen
The detection of viral antigens directly in clinical specimens
or cell cultures has become an essential component of the
methodological repertoire of diagnostic virology. These meth-
ods can provide diagnostic information within a few hours of
the receipt of the specimen. The lack of requirement for virus
viability is another important advantage over viral culture,
especially when specimen transport time is prolonged or
otherwise suboptimal. Antigen detection methods can be
applied when the following conditions are met: (i) viral antigen
is expressed and is present in an accessible specimen, (ii) an
appropriate antibody is available, (iii) antigenic variability does
not preclude recognition by immunologic reagents of different
strains of the target virus and (iv) the antigen being detected is
sufficiently stable so that it does not degrade during transport
and processing of the specimen. Methods used for viral antigen
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noperoxidase staining (IS) and enzyme immunoassay (EIA).
Fluorescent antibody staining
FAs is widely used for detection of cell associated viral
antigens. In the direct format, a fluorescent label, usually
fluorescein isothiocyanate (FITC), is conjugated directly to the
antibody that recognizes the viral antigen. In the indirect
format, the antiviral antibody is unlabeled and is detected by a
second antibody that recognizes immunoglobulins from the
animal species of origin of the antiviral antibody. The second
antibody carries the fluorescent label. After staining, the
specimen is viewed with epiilumination using ultraviolet light
of the wavelength needed to excite the fluorescent label. The
direct method is simpler to use but requires conjugation of each
antiviral antibody with the fluorescent label. The indirect
method is slightly more sensitive and more versatile because
only the antiimunoglobulin antibody has to be conjugated with
the fluorescent label. The FAs method is widely used for the
detection of HSV and hCMV viruses.
Immunoperoxidase staining
IS is similar in principle to FAs except that horseradish
peroxidase is used in place of a fluorescent label. The
advantage of this method is that the staining can be viewed
by light microscopy, thus obviating the need for a fluorescent
microscope. The disadvantages of the IP method are that it is
more cumbersome that FAs, and endogenous peroxidases in
some specimens can produce background staining.
Enzyme immunoassay
EIA is a widely used method that can be applied to the
detection of antigens regardless of whether they are cell
associated. Since intact cells in the specimen are not required,
specimen integrity is less important than for FAs and IS.
Advantages of EIA include applicability to diverse specimens
and potential for automation. Viruses for which antigen EIAs
have been widely used are HSV, HBV and HIV.
Serology
The measurement of antiviral antibodies was one of the first
methods used for the specific diagnosis of viral infections. The
role of serology in the viral diagnosis of the cell cultures may
be to determine the immune status of donors of biological
materials. It is important to use sensitive assays, such as EIA,
immunofluorescence, Western blot assays, etc. However,
research has shown that the detection of antibodies exclusively
runs the risk of samples for tests being taken during an
antibody-negative window period of these infections, where an
individual has been exposed to viral infection and indeed can
be viremic (Hitzler and Runkel, 2001). This finding has led to
the introduction of nucleic acid amplification techniques, such
as polymerase chain reaction (PCR), in which the presence of a
virus can be observed by means of the amplification of
sequences in the viral genome. The addition of nucleic acid test
methods to screening of tissue donors, and to the testing ofderived cell lines, should reduce the risk of these infections
among recipients of stem cell lines (Zou et al., 2004).
Molecular methods
Diagnostic virology is being revolutionized by the applica-
tion of nucleic acid detection techniques (Tang et al., 1997).
Nucleic acid-based diagnostic tests detect only the specific virus
to which the diagnostic reagent is directed. These methods
detect specific nucleic acid sequences and can be applied to the
detection of virtually any virus. Depending on the target
sequence, the assays can be specific for a single virus species
or for a group of related viruses. Nucleic acid amplification
assays are particularly attractive for viruses that are difficult or
impossible to culture, viruses that grow slowly in culture and
viruses for which antigen detection cannot be applied because
of antigenic diversity or because the level of viral antigen is too
low to permit successful detection.
PCR is the prototype of target amplification assays invented
by Kary Mullis in 1983 (Mullis and Faloona, 1987; Mullis,
1990). PCR is based on the ability of DNA polymerase to copy a
strand of DNA by elongation of complementary strands initiated
from a pair of closely spaced chemically synthesized oligonu-
cleotide primers and includes repeated cycles of amplifying
selected nucleic acid sequences (Mullis and Faloona, 1987;
Mullis, 1990). After PCR amplification, the PCR product (or
amplicon) is detected by gel electrophoresis or one of several
probe-hybridization techniques, such as Southern blot.
Numerous modifications of the standard PCR procedure
have been developed since its inception (Erlich et al., 1991;
Wagar, 1996). Some of these modifications effectively expand
the diagnostic capabilities of PCR and have increased its utility
in the microbiology laboratory. RT-PCR was developed to
amplify RNA targets. In this process, RNA targets are first
converted to complementary DNA (cDNA) by reverse tran-
scriptase (RT), and then amplified by PCR. RT-PCR has played
an important role in diagnosing RNA containing virus infec-
tions (Young et al., 1993).
Several new PCR assays have been developed in which the
synthesis of the PCR product is detected in real-time (Real-
time quantitative PCR) (Gibson et al., 1996; Heid et al., 1996).
Real-time quantitative PCR is a homogeneous method that
includes both amplification and analysis with no need for slab
gels, radioactivity or sample manipulation. Reaction products
are detected with a fluorescence detection system consisting of
a light-emitting diode that delivers excitation light to each
reaction tube and an optical unit with three detection channels
to record emitted light. The fluorescence of DNA dyes or
probes is monitored each cycle during PCR. The simplest
system for detection of real-time PCR products uses the DNA-
binding dye SYBR Green, which fluoresces when its binds to
double-stranded DNA. These methods have several important
advantages over conventional PCR. Since the accumulation of
PCR product is monitored in the reaction tube, no separate
detection method, such as gel electrophoresis, is required, thus
shortening the effective assay markedly. Furthermore, the
possibility of contamination by amplicons is decreased because
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contents after completion of PCR. The use of multiple
fluorescent dyes with different emission wavelengths makes
it possible to perform multiplex reactions with simultaneous
amplification of more than one product. Moreover, other
molecular methods have been described and introduced for
the viral diagnosis, like nucleic acid probes (Denniston et al.,
1986), Branched DNA signal amplification (Urdea et al.,
1991), nested PCR (Erlich et al., 1991) and multiplex PCR
(Dineva et al., 2005), etc. Real-time multiplex PCR can analyze
multiple viruses simultaneously within a single reaction. The
main advantages of multiplexing over single-target analysis are
the ability to provide internal controls, lower reagent costs and
preservation of precious samples. Multiplexing can be partic-
ularly important when there is a need to analyze several viruses
from the samples. There are several assays that use a real-time
multiplex RT-PCR technology for diagnosis of hepatitis B
virus, hepatitis C virus and HIV-1 virus (Candotti et al., 2004).
There are other authors who have described several assays
using this procedures for retroviruses (Vet et al., 1999) and
herpesviruses (O’Neill et al., 2003).
The advantages of molecular methods, especially the PCR
technique, are their extremely high sensitivity (they may detect
down to one viral genome per sample volume), they are easy to
set up and have a fast turnaround time.
However, the main inconvenience is that for each virus or
group of virus one PCR is necessary, so if the amount of viruses
to carry out is large, these techniques are the same unviable for
the laboratory.
Test for retroviruses
Retroviruses are one of the main contaminants of the cell
cultures. For these viruses, reverse transcriptase assays,
electron microscopy techniques and infectivity assays must
be included. A variety of infectivity assays are available for
rodent cell lines or stem cell lines with murine feeders. There
are two retrovirus infectivity assays for the ecotropic and
xenotropic viruses: XC plaque assay using indicator cells (XC)
to form syncytia (plaques) for detection of ecotropic viruses
(Lenz and Haseltine, 1983) and mink S+L assay for the
detection of xenotropic viruses (Li et al., 1999). However,
these tests are not suitable to detect and quantify the levels of
the ecotropic recombinant virus, thus a serological focus assay,
based on specific antimurine leukemia virus (MuLV) viral
envelope antibodies is required to detect ecotropic recombi-
nant virus (Deo et al., 1994). Moreover, for low levels of
murine retroviruses, amplification may be achieved using
cocultivation of cells with a susceptible cell line such as Mus
dunni cells.
The reverse transcriptase assay is an enzymatic technique
to detect the presence of extracellular retrovirus particles. This
assay is based on the ability of reverse transcriptase
associated with retroviruses to synthesize radiolabeled nucleo-
tides into complementary DNA (cDNA) copied from syn-
thetic templates. Due to the fact that a variety of enzymes are
capable of incorporating labeled deoxynucleotide into an acid-insoluble material, this assay is susceptible to false positives.
A useful test for eliminating false positives is to compare the
results from both a DNA template and a ribonucleic acid
(RNA) template because cellular DNA polymerase and viral
reverse transcriptase have different template preferences.
Furthermore, the PCR-based reverse transcriptase assay is
more sensitive than the standard enzymatic reverse transcriptase
assay.
Electron microscopy (see below) is used to visualize both
the ultrastructural morphology of the cell substrate and the
presence of virus and virus-like particles.
Microarrays methods for viruses
The development of microarrays has been fueled by the
application of robotic technology to routine molecular biology,
rather than by any fundamental breakthrough. Southern and
Northern blotting techniques for the detection of specific DNA
and mRNA species provided the technological basis for
microarray hybridization.
The construction of arrays involves the spotting of specific
DNA sequences on a glass slide or small silicon chip by
photolithographic combinatorial chemistry methods similar to
those used to make electronic chips. Membrane-based arrays
may be in the format of line probe blots. The results of
hybridization between the bound probe and labeled sequences
in the sample applied and tested are revealed by scanning or
imaging the array surface. Confocal microscopy is used to scan
the chip, detecting fluorescent signals that reveal hybridization
at precise locations on the chip. Use of probes representing all
possible nucleotide sequence variations within a target se-
quence allows rapid determination of nucleotide sequence
(Pease et al., 1994). High density arrays, which may have
thousands of individual probes per cm2, are referred to as
microarrays. These microarrays on silicon surfaces are there-
fore known as ‘‘DNA chips’’. As many DNA sequences can be
present on a slide, it is possible for microarray analysis to test
for multiple pathogens (including viruses) simultaneously.
The first application in diagnostic virology has been for rapid
sequencing to detect HIV mutations associated with resistance
to antiretroviral drugs (Kozal et al., 1996). Other roles in
virology are in diagnosis, to recognize the causative agent of an
illness; for molecular typing (e.g. patient management, epide-
miological reasons, purposes related to vaccine use) and in
research, to investigate the interactions between the virus and
the host cells (Clewley, 2004). The RNA expression of human
CMV in cell culture in the presence or absence of cyclohex-
imide or ganciclovir was analyzed with an array of oligonucleo-
tides representing human CMV ORFs (Chambers et al., 1999).
Other groups have developed microarrays that detect simulta-
neously and discriminate several viruses like orthopoxvirus
species (Laassri et al., 2003), respiratory viruses (Coiras et al.,
2005), herpesviruses, enteroviruses and flaviviruses (Korimbo-
cus et al., 2005) and hepatitis C virus (Xu et al., 2005). Also,
Wilson et al. (2002) developed a multi-pathogen identification
microarray system for the identification of 18 pathogenic
prokaryotes, eukaryotes and viruses.
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their use of a large number of species-specific oligoprobes and
their ability to analyze multiple samples in a short time, offers
clear advantages. However, such techniques will need to be
carefully validated for sensitivity and specificity before being
applied in the safety testing of human tissue products and stem
cell lines for therapy.
Table 1 shows a comparison of diagnostic methods for
viruses.
Proteomic analysis for viruses
Proteomics also holds a key position in the new functional
genomics biology and is a term for large scale analysis of
proteins. Proteomics encompasses different methods to identify
all the proteins present in a cell or tissue.
Protein arrays are being prepared with antigens or antibodies
bound to a solid phase (analogous to oligonucleotide or
amplicon probes) and used to capture specific antibodies or
antigens (Emili and Cagney, 2000; Walter et al., 2000).
Essentially, these are immunoassays in a microarray format
(Schweitzer and Kingsmore, 2002). A protein array has been
described for ToRCH screening and Toxoplasma gondii,
rubella virus, CMV and HSV-1 and 2 antigens were printed
on glass slides. The slides were first incubated with serum
samples and subsequently with fluorescently labeled secondary
antibodies. Human IgG and IgM bound to the printed antigens
were detected by confocal scanning microscopy. Good
concordance was obtained between the microarray results and
those of ELISAs (Mezzasoma et al., 2002). A microarray of
oligosaccharides on nitrocellulose has been developed to
capture carbohydrate-recognizing proteins, and it might be
possible to develop this for viral diagnosis (Fukui et al., 2002).
Biosensors have been defined as small devices which use
biological reactions to detect target analytes (Wang, 2000).
There are two ways of doing this; bioaffinity arrays involve
the target analyte binding to a ligand immobilized on a solid
phase (e.g. an oligonucleotide) and, instead of there being a
necessity for detection of hybridization of the probe and target
by colorimetric or radioactive means, the hybridization is
detected by electronic means. Biocatalytic arrays involve anTable 1




Only method available for some
viruses; used to study pathogenesis
Cell culture Used to study and quantify
most viruses; sensitive
Antigen detection Rapid; for viruses which
cannot be cultured
Serology Rapid; sensitive; can be
quantitative; automation
Nucleic acid-based Rapid; sensitivity
Microarrays Used for a big quantity of viruses
Electron microscopy Rapid; sensitivity; teaching value;
absence of viral viability; identification
of new agentsimmobilized enzyme being used to recognize the substrate of
the enzyme, which is, in this case, the target of the array. A
signal is generated when the enzyme catalyzes a specific
reaction because of the presence of the target in the analyte
applied to the array. The reaction may be recognized either by
colorimetric ally or via an electronic transducer at the surface
of the array.
With more technological advances, protein/antibody arrays
are likely to impact initially on infectious disease research with
profiling sera, body fluids to discover diagnostic markers of
particular infections. Proteomic techniques also will offer the
potential for discovering markers for diagnostic tests of viral
infections in vitro (e.g. stem cell cultures).
Diagnostic methods for prion particles
An interesting potential for infected cell cultures may be the
discovery of biological markers of prion infection, mainly by
comparing control versus infected cultures. This type of
experiment was first performed at a genetic level. With the
development of sophisticated proteomic approaches, several
groups are looking for differentially expressed proteins that
could be used as diagnostic markers or at least could give some
clue as to the physiopathological event leading to prion
propagation. Having developed cell lines highly susceptible
to prion infection (Bosque and Prusiner, 2000; Nishida et al.,
2000), another potential of cell culture consists of the detection
of infectivity in various biological samples.
The main sources of transmission of prion proteins to
culture cells are the bovine fetal serum, the feeder cells from
murine animals and the biological products from donors with
TSE to establish stem cell lines. In stem cell banks, there is an
urgent need for tests for the agents of TSEs such as the
Creutzfeldt–Jakob disease (U.S. Food and Drugs Administra-
tion, 1999). At the moment, there are several types of tests that
can be used for this question.
Detection of antibodies from prion proteins
The cell prion protein (PrPc) is essential for pathogenesis
and transmission of prion diseases (Prusiner, 1989). During theDisadvantages
Expensive; slow; complex systems–complex results
Slow; technically demanding
Technically demanding; equipment is expensive
Difficult interpretation; sensitivity variable
Expensive
Sensitivity and specificity non demonstrated;
absence of evaluation
Cost elevate; complexity of maintaining; requires
trained operator; requires high concentration of viral particles
Table 2
Examples of specific viruses that may be transmitted in transplanted cells and
cause serious diseases and currently available screening tests
Viruses Diagnostic tests





CMV NAT, culture, EM, serologya
EBV NAT, serologya
Prions WB, ELISA
Viruses of animal origin
BVDV NAT (RT-PCR), EM
Hantaan virus APT, EM
Reovirus-3 APT, EM
Sendai virus APT, EM
Lactic dehydrogenase virus APT, EM
Lymphocitic choriomeningitis virus APT, EM
Prions WB, ELISA
Unknown viruses EM
NAT: nucleic acid test (PCR, RT-PCR); EM: electron microscopy; APT:
antibodies production tests (MAP, RAP, HAP); WB: Western blot; ELISA:
enzyme-linked immunosorbent assay; BVDV: bovine viral diarrhea virus.
a Serology: for donors of biological products.
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form of PrP, designated PrPSc, accumulates mainly in the brain,
and may be the main or only constituent of the prion
(McKinley et al., 1991). The detection of this protein can be
carried out by means of antibodies of the monoclonal IgG1
subtype, anti-PrP 6H4 (Enari et al., 2001; Parizek et al., 2001);
this antibody recognizes the sequence DYEDRYYRE in the
prion protein (human PrP: amino acids 144–152). This
sequence is conserved in most known mammalian PrP
sequences (human, cattle, sheep, rabbit, mink and a variety
of primates). 6H4 can be used for Western blotting and ELISA
(Prionics, 2002). There are other monoclonal antibodies for
prion protein such as 34C9 that recognizes the sequence
LIHFG in the bovine prion protein and a polyclonal antibody
R029 that also recognizes bovine PrP.
Recently, Sanquin reagents (Sanquin, 2005) has developed a
new monoclonal antiprion antibody for use in research
applications (clone 1E4). In contrast to many other antibodies
used for detection of prion protein, 1E4 has a broad species
reactivity. Detection of prion protein has been demonstrated
with Western blot for humans, cattle, sheep, deer, mice and
hamsters. Most of the currently available TSE tests are based
on the fact that PrPc, normal prion protein, is digested by
proteinase k, whereas PrPSc, TSE specific prion, is relatively
resistant to degradation by proteases. The special feature of
1E4 is that its epitope is almost hidden on non-digested bovine
PrPSc, but after proteinase K digestion, the epitope becomes
available resulting in a significant increased detection. After
digestion with protease K, 1E4 binds to PrPSc with high
affinity, whereas it has a low affinity for non-digested PrPSc.
The 1E4 antibody has been tested in a broad variety of
methods, such as Western blot, RIA, ELISA, EliBlot, FACS
and immunohistochemistry.
Cyclic amplification of protein misfolding
Saborio et al. (2001) have developed a procedure, concep-
tually similar to polymerase chain reaction cycling, involving
cyclic amplification of protein misfolding PrPSc. This method
could allow a rapid conversion of excess PrPc into a protease
resistant PrPSc-like form. In this method, aggregates formed
when PrPSc is incubated with PrPc are disrupted by sonication
to generate multiple smaller units for the continued formation
of new PrPSc. After cycling amplification, more than 97% of
the protease resistant PrP present in the sample correspond to
newly converted protein. This method could be applied to
diagnose the presence of undetectable prion infectious agent in
tissues and biological fluids. In this respect, recently, Castilla et
al. (2005) have been the first to detect the resistant-protein
PrPSc biochemically in hamster blood by means of the cyclic
amplification of protein misfolding. This procedure enables
detection of prions in blood with 89% sensitivity and 100%
specificity. The high level of sensitivity and specificity
indicated that this assay offers promise for the design of a
sensitive biochemical test for blood diagnosis of transmissible
spongiform encephalopathies. The implementation of a similar
blood-detection procedure for humans and culture-detectionmethod for stem cell lines undoubtedly contributes to
minimizing the risk of infection with agents causing transmis-
sible spongiform encephalopathies.
In vivo assays with transgenic mice
The diagnosis of infections produced by TSEs can be
carried out by means of the detection of prionic protein (PrPSc)
by different methods (see below). Although the specificity of
these diagnostic methods is nearly 100% (Ironside, 1996; Lee
et al., 2000; Wadsworth et al., 2001), the sensitivity is still
inadequate to assure the value of a negative result. An
alternative to these methods would consist of the use of
transgenic mice; these would be vaccinated with tissues or
fluids that have unknown infectivity of the cell lines which
have used bovine serum to be obtained.
Conclusions
Stem cell banks arise from the necessity to guarantee the
existence of an appropriate source of cell lines in a
standardized way for their use in research or human therapies
through clinical trials. Moreover, these establishments should
assure the safety of biological products for use in cell therapy.
The major risks associated with the use of biological
products in regenerative medicine are related to cell contam-
ination. These include both serious human pathogens but also
human and animal viruses and prions capable of multiplying
and producing transmissible infectious diseases. Selecting and
testing of stem cell lines and biotechnological products (e.g.
bovine serum, tripsine, culture media) is one part of a strategy
for establishing a viral safety program (Cobo et al., 2006).
While the technology to avoid the animal products in the
Table 3
Virus tests recommended in the characterization of cell lines (modified from
Dellepiane et al., 2000 and EMEA, 1997)
Test Master bank Work bank Cell at the limit
Electron microscopy +  +
Reverse transcriptasea +  +
In vitro cell inoculation +  +
In vivo animal inoculation +  +
Antibody production testsb +  
Infectivityc +  +
Other virus specific testsd +  +
a Not necessary if positive by retrovirus infectivity test.
b e.g., MAP, RAP, HAP—Usually applicable for rodent cell lines.
c For retroviruses and other endogenous viruses.
d Tests for cell lines derived from human, non-human primate or other cell
lines as appropriate.
Minireview8culture manufacturing is being developed, the safety of the
human and/or animal products used in the cell cultures with
respect to viral and prion contamination could be obtained for
application of an exhaustive program of viral screening by
means the combination of techniques above-mentioned (Tables
2 and 3). The presence of viruses (including non-pathogenic
types) or prions in a human therapeutic product would most
likely render it unacceptable for clinical use.
At the moment, the cell banks must have a panel of tests to
detect serious pathogens like endogenous viruses, exogenous
viruses and prions. This panel of tests should necessarily include
reverse transcriptase detection as a general test for retroviruses,
electron microscopy that can detect different kinds of viral
particles and characterize many unknown isolates present in cell
cultures and molecular techniques like PCR (conventional or
real-time) and RT-PCR tests to include all the viruses that we
know pose a risk to the product. For prion detection, these banks
must have a procedure based on the Western blot or ELISA
technology for the detection of antibodies (e.g. 6H4, 1E4) that
can be present in the cell cultures. Some of these tests may also
need to be applied to culture reagents of animal origin, and any
testing performed by the manufacturer should be carefully
evaluated before accepting the reagents for use.
With respect to the use of ‘‘feeder cells’’ of animal origin
(e.g. murine) for embryonic stem cell culture, there is a need to
evaluate several viruses that are capable of infecting humans or
primates and that potentially can cause serious infections in
laboratory workers. For these viruses, the antibodies produc-
tion tests (e.g. MAP, RAP, HAP) are the most convenient
procedures in addition to the evaluation by means of electron
microscopy.
Several tests could be included in the screening of other
biological products for a wide range of viruses: the in vitro cell
culture assay and the study in animals (EMEA, 1997). These are
long standing techniques that rely on the ability of many viruses
to cause cytopathic changes in cell culture or clinical changes in
animals. However, there is a difficulty for implementation in
most of the laboratories due to the need for specialized facilities
and expertise, relatively prolonged time to detection (e.g. can
prove difficult to implement the testing of time critical
products) and the high cost.In the immediate future, the technologies based on the use
of hybridization chips, using microarrays of immobilized
oligonucleotides or antigens/antibodies for viruses, and the
method of cyclic amplification of protein misfolding PrPSc for
prions, can provide a rapid and useful methodology of the
identification of contaminants. In our opinion, there is a need to
design and to implement this methodology in stem cell
cultures, so new research will be needed.
Finally, it is not possible to assert the absolute absence of
viral contaminants because of both the impossibility of
covering all potential viral contaminants and the absence of
adequate levels of sensitivity and specificity of diagnostic
techniques in several cases. So, stem cell banks could
potentially permit transmission of some of these viral
contaminants to many patients receiving future stem cell
therapies where the balance of risk and benefit may be
different.
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